| Thu, Dec 10, 2009 | | • | UPDATE - Glaxo plans to outgrow rivals in emerging markets
at Reuters (Thu, Dec 10)
| | Thu, Dec 3, 2009 | | • | EURO BONDS-AKZO, Delta Lloyd, InterContinental, KA Finanz
at Reuters (Thu, Dec 3)
| | Tue, Nov 10, 2009 | | • | Ismail Kola joins UCB as Executive Vice President, UCB & President of UCB New Medicines(TM)
Marketwire (Tue, Nov 10)
| | Thu, Oct 22, 2009 | | • | Interim Report - Promising early results for UCB's new products
Marketwire (Thu, Oct 22)
| | Mon, Oct 5, 2009 | | • | Cimzia®, the only PEGylated anti-TNF, approved in Europe and available in a syringe designed in partnership with OXO Good Grips®
Marketwire (Mon, Oct 5)
| | Mon, Sep 28, 2009 | | • | UCB and AstraZeneca form alliance for the commercialization of Cimzia(R) in Brazil
Marketwire (Mon, Sep 28)
| | Thu, Aug 27, 2009 | | • | UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus (SLE)
Marketwire (Thu, Aug 27)
| | Mon, Aug 24, 2009 | | • | UCB and Novartis to expand cooperation in Germany
Marketwire (Mon, Aug 24)
| | Wed, Aug 12, 2009 | | • | UCB and its design partners, OXO(R) and Smart Design, win 2009 "Red Dot: Communication Design"
Marketwire (Wed, Aug 12)
| | Fri, Jul 31, 2009 | | • | UCB progress: new product launches and financials on track
Marketwire (Fri, Jul 31)
| | Fri, Jul 24, 2009 | | • | UCB receives CHMP positive opinion on Keppra(R) for infants and young children with partial-onset epilepsy
Marketwire (Fri, Jul 24)
| | Tue, Jun 30, 2009 | | • | UCB and Biogen Idec discontinue Phase II clinical trial of CDP323
Marketwire (Tue, Jun 30)
| | Mon, Jun 29, 2009 | | • | UCB brings Neupro(R) back to all patients in Europe
Marketwire (Mon, Jun 29)
| | Fri, Jun 26, 2009 | | • | Cimzia(R), the only PEGylated anti-TNF, recommended for approval in the EU for rheumatoid arthritis
Marketwire (Fri, Jun 26)
| | Fri, May 29, 2009 | | • | UCB receives CHMP positive opinion on bringing Neupro(R) back to all patients in Europe
Marketwire (Fri, May 29)
| | Tue, May 26, 2009 | | • | UCB launches Vimpat(R) in the U.S. for add-on treatment of epilepsy in adults
Marketwire (Tue, May 26)
| | Wed, May 20, 2009 | | • | Change in UCB's Executive Committee
Marketwire (Wed, May 20)
| | Thu, May 14, 2009 | | • | Partnership unites UCB with consumer product innovator OXO(R)
Marketwire (Thu, May 14)
| | Wed, May 13, 2009 | | • | UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
Marketwire (Wed, May 13)
| | Fri, May 8, 2009 | | • | UCB seeking to acquire remaining Schwarz Pharma shares
Marketwire (Fri, May 8)
|
Add UCB.BR News to My Yahoo!:
 
| |
|
0.47% Nasdaq 0.00%
0.52 (1.70%) 
Headlines
